1. Home
  2. DRUG vs JYNT Comparison

DRUG vs JYNT Comparison

Compare DRUG & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRUG
  • JYNT
  • Stock Information
  • Founded
  • DRUG 2019
  • JYNT 2010
  • Country
  • DRUG United States
  • JYNT United States
  • Employees
  • DRUG N/A
  • JYNT N/A
  • Industry
  • DRUG Pharmaceuticals and Biotechnology
  • JYNT Multi-Sector Companies
  • Sector
  • DRUG Health Care
  • JYNT Miscellaneous
  • Exchange
  • DRUG Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • DRUG 199.7M
  • JYNT 170.3M
  • IPO Year
  • DRUG N/A
  • JYNT 2014
  • Fundamental
  • Price
  • DRUG $43.96
  • JYNT $10.61
  • Analyst Decision
  • DRUG Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • DRUG 8
  • JYNT 3
  • Target Price
  • DRUG $83.60
  • JYNT $16.33
  • AVG Volume (30 Days)
  • DRUG 53.0K
  • JYNT 69.8K
  • Earning Date
  • DRUG 08-11-2025
  • JYNT 08-07-2025
  • Dividend Yield
  • DRUG N/A
  • JYNT N/A
  • EPS Growth
  • DRUG N/A
  • JYNT N/A
  • EPS
  • DRUG N/A
  • JYNT N/A
  • Revenue
  • DRUG N/A
  • JYNT $53,449,713.00
  • Revenue This Year
  • DRUG N/A
  • JYNT $8.06
  • Revenue Next Year
  • DRUG N/A
  • JYNT $11.18
  • P/E Ratio
  • DRUG N/A
  • JYNT N/A
  • Revenue Growth
  • DRUG N/A
  • JYNT 277.36
  • 52 Week Low
  • DRUG $0.94
  • JYNT $9.58
  • 52 Week High
  • DRUG $79.02
  • JYNT $13.47
  • Technical
  • Relative Strength Index (RSI)
  • DRUG 69.20
  • JYNT 43.73
  • Support Level
  • DRUG $34.19
  • JYNT $10.18
  • Resistance Level
  • DRUG $46.13
  • JYNT $11.00
  • Average True Range (ATR)
  • DRUG 3.38
  • JYNT 0.40
  • MACD
  • DRUG 0.26
  • JYNT -0.04
  • Stochastic Oscillator
  • DRUG 82.17
  • JYNT 42.15

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: